Compare KBH & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | ARQT |
|---|---|---|
| Founded | 1957 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 1994 | 2020 |
| Metric | KBH | ARQT |
|---|---|---|
| Price | $56.12 | $22.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $56.17 | $34.00 |
| AVG Volume (30 Days) | ★ 1.2M | 958.4K |
| Earning Date | 03-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $4,547,002,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | $9.23 | $29.39 |
| P/E Ratio | $106.77 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $48.17 | $12.42 |
| 52 Week High | $68.71 | $31.77 |
| Indicator | KBH | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 42.73 |
| Support Level | $55.18 | $22.56 |
| Resistance Level | $63.51 | $23.46 |
| Average True Range (ATR) | 1.40 | 0.89 |
| MACD | 0.85 | -0.04 |
| Stochastic Oscillator | 85.61 | 10.93 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.